Clinical Trial Update: The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of gefapixant (MK-7264) in participants with renal insufficiency completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency

Drugs mentioned

• Gefapixant (gefapixant)
• MK-7264 (MK-7264)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2019-08-02